Pharmaceutical companies are the industry leader in revenue and profits.
According to the Federal Trade Commission (FTC), pharmaceutical companies earn $1.6 trillion in sales and $5.9 trillion in net income annually.
Their revenue exceeds the gross domestic product (GDP) by about $6 trillion a year, which is roughly equivalent to about 9.7% of the economy.
In addition to generating $6.6 billion in revenue each year, pharmaceutical companies generate nearly $3.4 trillion in profit, and generate $2.2 trillion in capital gains annually.
In other words, the bottom line is that these companies have a lot of cash on hand and can spend it on things that are in the best interests of their shareholders, like paying dividends.
The pharmaceutical industry is also heavily dependent on research and development.
Companies that have the most patents and patents that are assigned to them can receive royalties, and that is one of the main reasons that pharmaceutical companies are able to earn billions of dollars each year in revenues.
With a strong patent portfolio, companies can also negotiate high prices on drugs.
And when companies are profitable, they are able, with minimal taxpayer support, to spend the profits on things like stock buybacks.
But in a world of shrinking government funding, these companies can afford to pay little attention to the needs of their consumers and, as a result, many of them have gone on a spending spree in recent years.
In the US, pharmaceuticals spent about $3 trillion in 2013, according to the National Institute of Health.
That’s roughly $200 billion more than they spent in 2008.
But the amount of spending by these companies has actually increased by $1 trillion since 2009, when they had a net income of just $300 million.
While the pharmaceutical industry’s profits have skyrocketed, their share of the overall economy has declined.
In 2012, it made up 18.5% of GDP.
By 2019, the share of GDP that the pharmaceutical sector was responsible for was about 9%.
So, in a way, the pharmaceutical companies have been making a lot more money by spending money on stock buyback programs than they have been doing by investing in the U.S. economy.
However, the number of pharmaceuticals that make money from their stock buy back programs has decreased substantially over the last few years.
So, how did this trend come about?
According to a 2013 article in the Wall Street Journal, “Pharmaceutical stocks are an attractive investment for some because they offer a high return on investment and their stock prices are volatile.”
The Wall Street, however, notes that the “financial market is dominated by the stock market.”
In other parts of the world, drug companies are also relatively popular.
In fact, the United Kingdom is one example.
According a recent report from the UK Financial Times, the UK pharmaceutical sector generates about $1 billion in annual revenues and a total of $4.3 billion in profits.
As the report notes, there are over 2,300 drug companies in the UK, and they make up about 18% of total sales.
And yet, the government of the United States has been spending billions of taxpayer dollars on the pharmaceutical industries to support the drug companies.
According the Wall St. Journal, the “U.
S government has spent about £1.3 trillion on prescription drug prices since 2009 to help drugmakers raise money for research and clinical development, with more than half going to the pharmaceutical giants Pfizer and Johnson & Johnson.
The average annual increase in pharmaceutical prices since 2008 has been a record $10,700 per patient per year.”
According to an analysis by the Center for Responsive Politics, over $6 billion has been spent on lobbying since 2009 by the pharmaceutical and health care industry.
As of last year, more than 40,000 lobbyists were working for the pharmaceuticals.
In many cases, the lobbyists work for the companies, not the government.
In some cases, it’s not even clear that the lobbyists are actually representing the interests of the pharmaceutical firms.
Instead, the lobbying is designed to benefit the pharmaceutical manufacturers at the expense of taxpayers.
In 2016, the US government spent more than $3 billion on pharmaceutical lobbying.
This represents a whopping $2,700 in tax breaks to the drug makers and their lobbyists every single year.
According one report, the American Medical Association (AMA) estimates that the cost of lobbying the US Congress has cost the federal government $5 billion since 2010.
In 2017, the AMA estimated that the government has wasted $3,700 on lobbying over the past decade.
The report goes on to say that “the cost of such lobbying has risen significantly over the years and is now estimated at more than five times as much as the cost incurred by other federal agencies for lobbying activities, as well as a far higher share of these costs being incurred by the American public.”
And the costs of lobbying are increasing because